Cytek Biosciences Stock Forward View - 20 Period Moving Average
| CTKB Stock | USD 4.36 0.14 3.32% |
This forecast for Cytek Biosciences integrates publicly available signals - news flow, social activity, and sentiment trends - to generate a probabilistic view of where the stock is heading in the near term.
In the latest session, the short-cycle RSI for Cytek Biosciences stands at 43, indicating moderately negative momentum. This range suggests moderated price movement without extreme directional pressure.Momentum 43
Sell Extended
Oversold | Overbought |
Quarterly Earnings Growth 0.735 | EPS Estimate Next Quarter -0.04 | EPS Estimate Current Year -0.09 | EPS Estimate Next Year 0.045 | Wall Street Target Price 6 |
Hype-based context for Cytek Biosciences compares attention patterns with recent price movement. Options positioning and short interest provide sentiment context for Cytek Biosciences in this view.
Review both Payables Turnover and Days Of Inventory On Hand for comprehensive statements.
Cytek Biosciences Implied Volatility | 3.46 |
The Cytek Biosciences implied volatility level measures the annualized expected price range of Cytek Biosciences' stock as priced by options traders. A value of 30% means the market expects roughly a 30% range of price movement over the next year.
The 20 Period Moving Average forecasted value of Cytek Biosciences on the next trading day is expected to be 4.34 with a mean absolute deviation of 0.36 and the sum of the absolute errors of 15.15.Cytek Biosciences after-hype prediction price | USD 4.34 |
Hype indicators are listed alongside forecasting models, technical studies, analyst consensus, and earnings expectations.
Historical Fundamental Analysis of Cytek Biosciences can be used to cross-verify projections for Cytek Biosciences. The historical view provides additional context.Open Interest on 2026-04-17 Cytek Option Chain
This open interest summary for Cytek Biosciences reflects contract activity and helps frame liquidity and engagement.
Cytek Biosciences Additional Predictive Modules
Most predictive techniques to examine Cytek price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Cytek using various technical indicators. When you analyze Cytek charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Cytek Biosciences 20 Period Moving Average Price Forecast For the 11th of March 2026
Given 90 days horizon, the 20 Period Moving Average forecasted value of Cytek Biosciences on the next trading day is expected to be 4.34 with a mean absolute deviation of 0.36 , mean absolute percentage error of 0.21 , and the sum of the absolute errors of 15.15 .Please note that although there have been many attempts to predict Cytek Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Cytek Biosciences' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Cytek Biosciences Stock Forecast Pattern
| Backtest Cytek Biosciences | Cytek Biosciences Price Prediction | Research Analysis |
Cytek Biosciences Forecasted Value
This next-day forecast for Cytek Biosciences uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the 20 Period Moving Average forecasting method's relative quality and the estimations of the prediction error of Cytek Biosciences stock data series using in forecasting. Note that when a statistical model is used to represent Cytek Biosciences stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 81.6092 |
| Bias | Arithmetic mean of the errors | 0.183 |
| MAD | Mean absolute deviation | 0.3606 |
| MAPE | Mean absolute percentage error | 0.0768 |
| SAE | Sum of the absolute errors | 15.145 |
Mean reversion traders in Cytek Biosciences' look for price extremes that diverge materially from the historical norm, then position for the reversion that typically follows when the initial catalyst fades.
Cytek Biosciences After-Hype Price Density Analysis
Financial return distributions for assets like Cytek Biosciences are rarely normal. Cytek Biosciences' price distribution may exhibit fat tails - a higher probability of extreme outcomes than a Gaussian model would predict - making tail risk management essential for Cytek Biosciences investors.
Next price density |
| Expected price to next headline |
Cytek Biosciences Estimiated After-Hype Price Volatility
After analyzing Cytek Biosciences' historical price reactions to major news events, we derive statistically significant upside and downside boundaries for the next significant headline. Cytek Biosciences' after-hype downside and upside margins for the prediction period are 1.67 and 7.01, respectively. These boundaries reflect how Cytek Biosciences has historically moved in response to comparable catalysts.
Current Value
The after-hype framework applied to Cytek Biosciences assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Cytek Biosciences Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Cytek Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cytek Biosciences backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Cytek Biosciences, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.17 | 2.71 | 0.02 | 0.01 | 7 Events | 7 Events | In 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
4.36 | 4.34 | 0.46 |
|
Cytek Biosciences Hype Timeline
Cytek Biosciences is currently traded for 4.36. The entity has historical hype elasticity of -0.02, and average elasticity to hype of competition of 0.01. Cytek is forecasted to decline in value after the next headline, with the price expected to drop to 4.34. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.46%, whereas the daily expected return is currently at -0.17%. The volatility of related hype on Cytek Biosciences is about 5313.73%, with the expected price after the next announcement by competition of 4.37. About 65.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.59. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cytek Biosciences recorded a loss per share of 0.52. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in 7 days. Historical Fundamental Analysis of Cytek Biosciences can be used to cross-verify projections for Cytek Biosciences. The historical view provides additional context.Cytek Biosciences Related Hype Analysis
The comparative hype analysis table for Cytek Biosciences provides risk metrics - including hype elasticity, information ratio, and semi-deviation - for Cytek Biosciences' direct competitors. helping investors contextualize the relative news sensitivity of Cytek Biosciences.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| VREX | Varex Imaging Corp | 0.09 | 8 per month | 2.25 | 0.01 | 3.53 | -3.31 | 9.48 | |
| AVNS | Avanos Medical | 0.25 | 9 per month | 2.29 | 0.09 | 4.13 | -3.08 | 15.78 | |
| LAB | Standard Biotools | -0.11 | 7 per month | 0.00 | -0.11 | 7.10 | -6.12 | 27.04 | |
| CLPT | Clearpoint Neuro | 0.19 | 7 per month | 0.00 | -0.06 | 7.61 | -9.44 | 33.67 | |
| TMCI | Treace Medical Concepts | -0.12 | 9 per month | 0.00 | -0.23 | 6.35 | -6.37 | 22.21 | |
| SRDX | SurModics | 0.39 | 7 per month | 1.26 | 0.08 | 2.09 | -2.90 | 49.69 | |
| CBLL | CeriBell | -0.08 | 11 per month | 2.46 | 0.05 | 4.95 | -4.02 | 12.95 | |
| KIDS | Orthopediatrics Corp | 0.26 | 8 per month | 2.29 | 0.01 | 3.98 | -3.57 | 16.89 | |
| ORGO | Organogenesis Holdings | 0.09 | 7 per month | 0.00 | -0.21 | 4.17 | -9.98 | 22.73 | |
| ANGO | AngioDynamics | -0.45 | 10 per month | 0.00 | -0.08 | 3.81 | -4.55 | 17.87 |
Other Forecasting Options for Cytek Biosciences
Understanding Cytek Biosciences' price movement is a critical first step for any investor considering Cytek. The noise present in Cytek Stock price charts can easily mislead investors who rely solely on visual inspection.Cytek Biosciences Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cytek Biosciences stock to make a market-neutral strategy. Peer analysis of Cytek Biosciences could also be used in its relative valuation, which is a method of valuing Cytek Biosciences by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Cytek Biosciences Market Strength Events
Market strength indicators provide a structured view of how Cytek Biosciences stock is positioned relative to prevailing market trends. Investors use these tools to determine the best times to initiate or close positions in Cytek Biosciences.
Cytek Biosciences Risk Indicators
The analysis of Cytek Biosciences' risk metrics is one of the most important steps in accurately projecting its future price. This process involves measuring the level of investment risk in Cytek Biosciences' and determining how best to manage it.
| Mean Deviation | 1.92 | |||
| Standard Deviation | 2.65 | |||
| Variance | 7.01 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Cytek Biosciences
Coverage intensity for Cytek Biosciences matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Cytek Biosciences Short Properties
Short sentiment tied to Cytek Biosciences matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 127.7 M | |
| Cash And Short Term Investments | 261.5 M |
More Resources for Cytek Stock Analysis
Understanding Cytek Biosciences typically begins with financial statements and long-term trend review. Ratios and trend metrics help frame Cytek Biosciences' operating context. Below are reports that help frame Cytek Biosciences Stock in context:Historical Fundamental Analysis of Cytek Biosciences can be used to cross-verify projections for Cytek Biosciences. The historical view provides additional context. Discover how to invest in Cytek Stock by reading our How to Buy Cytek Stock guide.Analysis related to Cytek Biosciences should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Quarterly Earnings Growth 0.735 | Earnings Share -0.52 | Revenue Per Share | Quarterly Revenue Growth 0.081 | Return On Assets |
Cytek Biosciences market price can diverge from book value, the accounting figure shown on Cytek balance sheet. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Market price responds to sentiment, liquidity, and macro shifts, so gaps can appear. Valuation work aligns these measures into a single context.
It is useful to distinguish Cytek Biosciences' value from its trading price, which are computed with different methods. Context can include financial performance, operating efficiency, market trends, and peer comparisons. Market price reflects the current exchange level formed by active bids and offers.